Pharma BD Deal Intelligence
Not actually an acquisition — a $2.1B respiratory Anticalin collaboration whose lead asset failed toxicology and was fully terminated by AstraZeneca in 2023, gutting Pieris (70% layoffs) and contributing to its eventual reverse-merger exit.
Full analysis, sources & comparables →Peer-reviewed characterization of elarekibep as a first-in-class inhaled Anticalin targeting IL-4Rα for type 2 endotype asthma, validating the scientific…
AstraZeneca halted elarekibep Phase 2a trials after a 13-week dry-powder-inhaler tox study revealed inflammation-mediated lung tissue damage; Pieris shares…
Pieris announced restructuring and headcount reduction after losing AstraZeneca on elarekibep — the Anticalin respiratory franchise's centerpiece — calling…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca and Pieris entered a strategic collaboration to develop inhaled Anticalin-based respiratory therapies. Pieris received $45M upfront plus $12.5M for Phase 1 initiation of PRS-060 (~$57.5M near-term), with potential for up to $2.1B in development and commercial milestones plus tiered royalties. AstraZeneca funds all development; Pieris retains U.S. co-development/co-commercialization option from Phase 2a.
Not actually an acquisition — a $2.1B respiratory Anticalin collaboration whose lead asset failed toxicology and was fully terminated by AstraZeneca in 2023, gutting Pieris (70% layoffs) and contributing to its eventual reverse-merger exit.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Pieris Pharmaceuticals, Inc. (this deal) | 2017 | $2.2B | 16 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2017 deals · AstraZeneca PLC deals · Respiratory deals